Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell + cytokine-induced killer cell
- Development stage
- Unknown
- Lead developer
- Universiti Malaya
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Dendritic cell + cytokine-induced killer cell (DC+CIK) is an investigational cell-based immunotherapy being developed by the University of Malaya for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). This biologic therapy consists of two distinct cellular components: autologous dendritic cells (DCs) and cytokine-induced killer (CIK) cells. Dendritic cells are professional antigen-presenting cells that are prepared to prime and activate tumor-specific T-cell responses. CIK cells are a heterogeneous population of ex vivo-expanded effector lymphocytes, primarily CD3+CD56+ cells, that exhibit potent, non-MHC-restricted cytotoxicity against cancer cells, often mediated by the NKG2D receptor. The therapy is currently being evaluated in the Phase 2/3 DECIMATE 3.0 trial (NCT05955157) as a maintenance treatment in combination with the chemotherapy agent S-1 for patients with advanced PDAC who have achieved stable disease after first-line chemotherapy. The treatment aims to improve clinical benefit rates and reduce the population of circulating cancer stem cells.
- Other names
- DC+CIKDC-CIKDC+CIK immunotherapy
Beyond the preview
Go deeper on dendritic cell + cytokine-induced killer cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell + cytokine-induced killer cell.